Longterm carcinogenic effects of daily low emission phototherapy in psoriasis

Longterm carcinogenic effects of daily low emission phototherapy in psoriasis - UVTOX

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48614

Enrollment

110

Registered

2019-03-08

Start date

2019-05-13

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: >18 years old psoriasis;Depending on the research arm: - undergoing conventional phototherapy for at least 4 weken - undergoing low emission phototherapy for at least 18 maanden - not undergoing phototherapy or any systemic treatment for psoriasis

Exclusion criteria

Exclusion criteria: systemic medication for treatment of psoriasis unable to give informed consent

Design outcomes

Primary

Measure	Time frame
To ascertain the amount of UV-damage (p53 activation, thymidine dimers, apoptosis and γH2AX) is caused by the Dermasun treatment in psoriasis patients in comparison to conventional smallspectrum UV-treatment and no UV treatment.	—

Secondary

Measure	Time frame
Number of (pre-) cancerous skin lesions found at the biopsy time point Reported actual use of Dermasun by patients after having Dermasun in their homes for at least a year.	—

Countries

Netherlands

Outcome results